On Thursday, the Danish Health Authority allowed doctors in the country to use MSD's tablet treatment, Lagevrio (molnupiravir), to treat patients at risk of severe Covid-19 infections.
However, the drug is receiving criticism for inadequate effectiveness, reports Danish medical journal Ugeskrift for Læger. In the worst case, molnupiravir might have no effect at all.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.